Switch to:
Also traded in: Argentina, Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
NYSE:LLY's Cash-to-Debt is ranked lower than
71% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. NYSE:LLY: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:LLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.68 Max: 1.64
Current: 0.41
0.11
1.64
Equity-to-Asset 0.33
NYSE:LLY's Equity-to-Asset is ranked lower than
90% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:LLY: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:LLY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.44 Max: 0.67
Current: 0.33
0.23
0.67
Debt-to-Equity 0.81
NYSE:LLY's Debt-to-Equity is ranked lower than
87% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NYSE:LLY: 0.81 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:LLY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11  Med: 0.5 Max: 1.55
Current: 0.81
0.11
1.55
Debt-to-EBITDA 2.16
NYSE:LLY's Debt-to-EBITDA is ranked lower than
70% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. NYSE:LLY: 2.16 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:LLY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.7  Med: 1.39 Max: 241.62
Current: 2.16
0.7
241.62
Interest Coverage 18.91
NYSE:LLY's Interest Coverage is ranked lower than
65% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. NYSE:LLY: 18.91 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:LLY' s Interest Coverage Range Over the Past 10 Years
Min: 13.87  Med: 24.3 Max: 35.47
Current: 18.91
13.87
35.47
Piotroski F-Score: 5
Altman Z-Score: 3.41
Beneish M-Score: -2.75
WACC vs ROIC
4.21%
6.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 19.41
NYSE:LLY's Operating Margin % is ranked higher than
74% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. NYSE:LLY: 19.41 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:LLY' s Operating Margin % Range Over the Past 10 Years
Min: 13.65  Med: 22.62 Max: 29.17
Current: 19.41
13.65
29.17
Net Margin % 4.82
NYSE:LLY's Net Margin % is ranked lower than
72% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:LLY: 4.82 )
Ranked among companies with meaningful Net Margin % only.
NYSE:LLY' s Net Margin % Range Over the Past 10 Years
Min: -10.17  Med: 15.4 Max: 21.97
Current: 4.82
-10.17
21.97
ROE % 8.13
NYSE:LLY's ROE % is ranked lower than
69% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. NYSE:LLY: 8.13 )
Ranked among companies with meaningful ROE % only.
NYSE:LLY' s ROE % Range Over the Past 10 Years
Min: -20.47  Med: 24.03 Max: 53.25
Current: 8.13
-20.47
53.25
ROA % 2.66
NYSE:LLY's ROA % is ranked lower than
67% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. NYSE:LLY: 2.66 )
Ranked among companies with meaningful ROA % only.
NYSE:LLY' s ROA % Range Over the Past 10 Years
Min: -7.39  Med: 9.69 Max: 17.34
Current: 2.66
-7.39
17.34
ROC (Joel Greenblatt) % 40.19
NYSE:LLY's ROC (Joel Greenblatt) % is ranked higher than
70% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. NYSE:LLY: 40.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:LLY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.59  Med: 53.42 Max: 76.89
Current: 40.19
-11.59
76.89
3-Year Revenue Growth Rate 6.00
NYSE:LLY's 3-Year Revenue Growth Rate is ranked higher than
53% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NYSE:LLY: 6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:LLY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.7  Med: 6.3 Max: 14.3
Current: 6
-5.7
14.3
3-Year EBITDA Growth Rate -3.50
NYSE:LLY's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. NYSE:LLY: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:LLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -78.5  Med: 4.3 Max: 437.2
Current: -3.5
-78.5
437.2
GuruFocus has detected 7 Warning Signs with Eli Lilly and Co NYSE:LLY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:LLY's 30-Y Financials

Financials (Next Earnings Date: 2018-07-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

LLY Guru Trades in Q3 2017

Dodge & Cox 20,020,077 sh (+234.12%)
Mairs and Power 976,949 sh (+12.06%)
Ken Fisher 3,109,012 sh (+4.00%)
Vanguard Health Care Fund 28,110,470 sh (+0.13%)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 55,682,522 sh (-1.21%)
Murray Stahl 25,082 sh (-1.43%)
HOTCHKIS & WILEY 26,200 sh (-2.60%)
Mario Gabelli 73,850 sh (-3.84%)
Manning & Napier Advisors, Inc 23,077 sh (-6.96%)
Pioneer Investments 868,850 sh (-7.34%)
Jeremy Grantham 802,049 sh (-7.52%)
Sarah Ketterer 3,007,960 sh (-7.99%)
Jim Simons 4,049,205 sh (-28.90%)
Steven Cohen 600,000 sh (-53.06%)
Eaton Vance Worldwide Health Sciences Fund 590,237 sh (-8.62%)
» More
Q4 2017

LLY Guru Trades in Q4 2017

Ray Dalio 123,940 sh (New)
Caxton Associates 16,228 sh (New)
Joel Greenblatt 256,537 sh (New)
Pioneer Investments 1,832,626 sh (+110.93%)
Jeremy Grantham 980,849 sh (+22.29%)
Steven Cohen 646,800 sh (+7.80%)
Ken Fisher 3,309,599 sh (+6.45%)
Jim Simons 4,272,105 sh (+5.50%)
Mairs and Power 1,014,481 sh (+3.84%)
Dodge & Cox 20,181,287 sh (+0.81%)
Murray Stahl 25,082 sh (unchged)
PRIMECAP Management 55,152,577 sh (-0.95%)
Sarah Ketterer 2,880,032 sh (-4.25%)
HOTCHKIS & WILEY 24,900 sh (-4.96%)
Vanguard Health Care Fund 26,239,267 sh (-6.66%)
Mario Gabelli 52,100 sh (-29.45%)
Eaton Vance Worldwide Health Sciences Fund 559,742 sh (-5.17%)
» More
Q1 2018

LLY Guru Trades in Q1 2018

Paul Tudor Jones 47,542 sh (New)
Ray Dalio 225,798 sh (+82.18%)
Steven Cohen 898,691 sh (+38.94%)
Jeremy Grantham 1,329,349 sh (+35.53%)
Sarah Ketterer 3,705,960 sh (+28.68%)
Dodge & Cox 21,842,117 sh (+8.23%)
Ken Fisher 3,529,211 sh (+6.64%)
Mairs and Power 1,039,293 sh (+2.45%)
HOTCHKIS & WILEY 24,900 sh (unchged)
Caxton Associates Sold Out
PRIMECAP Management 54,546,783 sh (-1.10%)
Mario Gabelli 50,950 sh (-2.21%)
Murray Stahl 24,082 sh (-3.99%)
Vanguard Health Care Fund 24,989,415 sh (-4.76%)
Jim Simons 3,755,705 sh (-12.09%)
Pioneer Investments 1,021,968 sh (-44.23%)
Joel Greenblatt 90,625 sh (-64.67%)
Eaton Vance Worldwide Health Sciences Fund 430,672 sh (-23.06%)
» More
Q2 2018

LLY Guru Trades in Q2 2018

Ken Fisher 3,710,066 sh (+5.12%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:LLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Add 5.12%0.02%$75.7 - $86.88 $ 89.579%3,710,066
Vanguard Health Care Fund 2018-03-31 Reduce -4.76%0.23%$74.21 - $87.6 $ 89.5711%24,989,415
Dodge & Cox 2018-03-31 Add 8.23%0.1%$74.21 - $87.6 $ 89.5711%21,842,117
Ken Fisher 2018-03-31 Add 6.64%0.02%$74.21 - $87.6 $ 89.5711%3,529,211
Joel Greenblatt 2018-03-31 Reduce -64.67%0.2%$74.21 - $87.6 $ 89.5711%90,625
Mario Gabelli 2018-03-31 Reduce -2.21%$74.21 - $87.6 $ 89.5711%50,950
Vanguard Health Care Fund 2017-12-31 Reduce -6.66%0.34%$81.94 - $87.89 $ 89.575%26,239,267
Dodge & Cox 2017-12-31 Add 0.81%0.01%$81.94 - $87.89 $ 89.575%20,181,287
Ken Fisher 2017-12-31 Add 6.45%0.02%$81.94 - $87.89 $ 89.575%3,309,599
Joel Greenblatt 2017-12-31 New Buy0.31%$81.94 - $87.89 $ 89.575%256,537
Mario Gabelli 2017-12-31 Reduce -29.45%0.01%$81.94 - $87.89 $ 89.575%52,100
HOTCHKIS & WILEY 2017-12-31 Reduce -4.96%$81.94 - $87.89 $ 89.575%24,900
Vanguard Health Care Fund 2017-09-30 Add 0.13%0.01%$77.07 - $85.54 $ 89.579%28,110,470
Dodge & Cox 2017-09-30 Add 234.12%0.97%$77.07 - $85.54 $ 89.579%20,020,077
Ken Fisher 2017-09-30 Add 4.00%0.01%$77.07 - $85.54 $ 89.579%3,109,012
Mario Gabelli 2017-09-30 Reduce -3.84%$77.07 - $85.54 $ 89.579%73,850
HOTCHKIS & WILEY 2017-09-30 Reduce -2.60%$77.07 - $85.54 $ 89.579%26,200
Joel Greenblatt 2017-09-30 Sold Out 0.01%$77.07 - $85.54 $ 89.579%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:BMY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, NYSE:ABBV, TSE:4568, NYSE:MRK, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:LLY.Argentina, LILY34.Brazil, LLY.France, LLY.Germany, LLY.Mexico, LLY.Switzerland, LEL.UK,
Headquarter Location:USA
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market.

Guru Investment Theses on Eli Lilly and Co

Dodge & Cox Comments on Eli Lilly - Feb 13, 2018

During the second quarter of 2017, we initiated a position in Eli Lilly (NYSE:LLY), a leading drug company focused on branded pharmaceuticals and animal health products. As the only pharmaceutical company with a presence across all major drug classes in the diabetes field, it has an advantage in contracting and marketing products. Until recently, Eli Lilly was losing market share to Novo Nordisk and Sanofi in the key area of diabetes classes, given its smaller emerging markets footprint and lack of a basal insulin therapy. This trend reversed as Eli Lilly launched several new products during the last few years, and the company is now gaining share in most therapeutic areas within diabetes. Eli Lilly’s partnership with Boehringer Ingelheim, where costs and profits are shared 50/50, has been important in rejuvenating its diabetes portfolio.



After weathering two recent patent expirations, Eli Lilly is entering what could be an extended period of growth. The company’s four new drugs should each generate over $1 billion in annual sales. All of these recent product approvals have found commercial success and are driving future sales growth. If revenue grows as we expect, margins should improve significantly and boost earnings growth. The company has consistently had one of the better research and development (R&D) groups in the Pharmaceuticals industry due to its stable organization, thoughtful leadership, and high funding.



Most importantly, the company’s newly appointed CEO leads a competent management team that appears to be well aligned with the interests of long-term shareholders and capable of navigating competitive and regulatory risks. Eli Lilly was a 1.4% position in the portfolio on December 31.



From Dodge & Cox's fourth quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about Eli Lilly and Co

New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability
Primecap Management Keeps Buying Pros Holdings The transitioning company fits the bill of the outperforming but quiet firm
Outperforming firm Primecap Management said Thursday that it increased its position in Pros Holdings Inc. (NYSE:PRO) by 55.07% on June 30. Read more...
Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine
Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)
AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache
First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes

Ratios

vs
industry
vs
history
PE Ratio 83.71
LLY's PE Ratio is ranked lower than
99.99% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. LLY: 83.71 )
Ranked among companies with meaningful PE Ratio only.
LLY' s PE Ratio Range Over the Past 10 Years
Min: 7.44  Med: 15.55 Max: 83.84
Current: 83.71
7.44
83.84
Forward PE Ratio 17.36
LLY's Forward PE Ratio is ranked higher than
63% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. LLY: 17.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 83.71
LLY's PE Ratio without NRI is ranked lower than
99.99% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. LLY: 83.71 )
Ranked among companies with meaningful PE Ratio without NRI only.
LLY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.44  Med: 15.55 Max: 83.84
Current: 83.71
7.44
83.84
PB Ratio 6.74
LLY's PB Ratio is ranked lower than
82% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. LLY: 6.74 )
Ranked among companies with meaningful PB Ratio only.
LLY' s PB Ratio Range Over the Past 10 Years
Min: 2.52  Med: 4.17 Max: 8.26
Current: 6.74
2.52
8.26
PS Ratio 4.03
LLY's PS Ratio is ranked lower than
54% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. LLY: 4.03 )
Ranked among companies with meaningful PS Ratio only.
LLY' s PS Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.69 Max: 4.81
Current: 4.03
1.49
4.81
Price-to-Free-Cash-Flow 21.86
LLY's Price-to-Free-Cash-Flow is ranked higher than
63% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. LLY: 21.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LLY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.17  Med: 13.53 Max: 68.96
Current: 21.86
5.17
68.96
Price-to-Operating-Cash-Flow 16.50
LLY's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. LLY: 16.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LLY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.41  Med: 10.85 Max: 31.12
Current: 16.5
4.41
31.12
EV-to-EBIT 27.30
LLY's EV-to-EBIT is ranked lower than
79% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. LLY: 27.30 )
Ranked among companies with meaningful EV-to-EBIT only.
LLY' s EV-to-EBIT Range Over the Past 10 Years
Min: -303.9  Med: 11 Max: 39.9
Current: 27.3
-303.9
39.9
EV-to-EBITDA 19.22
LLY's EV-to-EBITDA is ranked lower than
67% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. LLY: 19.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
LLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 10.3 Max: 1132
Current: 19.22
4.8
1132
EV-to-Revenue 4.46
LLY's EV-to-Revenue is ranked lower than
58% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. LLY: 4.46 )
Ranked among companies with meaningful EV-to-Revenue only.
LLY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.7 Max: 5
Current: 4.46
1.6
5
Shiller PE Ratio 31.98
LLY's Shiller PE Ratio is ranked higher than
63% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. LLY: 31.98 )
Ranked among companies with meaningful Shiller PE Ratio only.
LLY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.83  Med: 18.1 Max: 32.04
Current: 31.98
10.83
32.04
Current Ratio 1.41
LLY's Current Ratio is ranked lower than
80% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. LLY: 1.41 )
Ranked among companies with meaningful Current Ratio only.
LLY' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.56 Max: 3
Current: 1.41
0.7
3
Quick Ratio 1.01
LLY's Quick Ratio is ranked lower than
77% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. LLY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
LLY' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.22 Max: 2.38
Current: 1.01
0.53
2.38
Days Inventory 252.95
LLY's Days Inventory is ranked lower than
90% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. LLY: 252.95 )
Ranked among companies with meaningful Days Inventory only.
LLY' s Days Inventory Range Over the Past 10 Years
Min: 173.48  Med: 216.93 Max: 252.95
Current: 252.95
173.48
252.95
Days Sales Outstanding 70.29
LLY's Days Sales Outstanding is ranked higher than
52% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. LLY: 70.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
LLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.79  Med: 55.57 Max: 72.55
Current: 70.29
49.79
72.55
Days Payable 73.27
LLY's Days Payable is ranked higher than
58% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. LLY: 73.27 )
Ranked among companies with meaningful Days Payable only.
LLY' s Days Payable Range Over the Past 10 Years
Min: 73.27  Med: 84.16 Max: 96.97
Current: 73.27
73.27
96.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.42
LLY's Dividend Yield % is ranked higher than
80% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. LLY: 2.42 )
Ranked among companies with meaningful Dividend Yield % only.
LLY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.24  Med: 3.62 Max: 6.79
Current: 2.42
2.24
6.79
Dividend Payout Ratio 1.98
LLY's Dividend Payout Ratio is ranked lower than
81% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. LLY: 1.98 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LLY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.52 Max: 1.98
Current: 1.98
0.43
1.98
3-Year Dividend Growth Rate 2.00
LLY's 3-Year Dividend Growth Rate is ranked lower than
62% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. LLY: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LLY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.9 Max: 20.2
Current: 2
0
20.2
Forward Dividend Yield % 2.51
LLY's Forward Dividend Yield % is ranked higher than
74% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. LLY: 2.51 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.58
LLY's 5-Year Yield-on-Cost % is ranked higher than
72% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. LLY: 2.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LLY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.39  Med: 3.86 Max: 7.24
Current: 2.58
2.39
7.24
3-Year Average Share Buyback Ratio 0.30
LLY's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. LLY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LLY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: -0.1 Max: 2
Current: 0.3
-3.1
2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 9.23
LLY's Price-to-Tangible-Book is ranked lower than
95% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. LLY: 9.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LLY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 6.68 Max: 33.46
Current: 9.23
3.22
33.46
Price-to-Intrinsic-Value-Projected-FCF 2.18
LLY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. LLY: 2.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LLY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.68  Med: 2.03 Max: 5.56
Current: 2.18
0.68
5.56
Price-to-Median-PS-Value 1.50
LLY's Price-to-Median-PS-Value is ranked lower than
68% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. LLY: 1.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LLY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.49 Max: 4
Current: 1.5
0.6
4
Price-to-Graham-Number 5.86
LLY's Price-to-Graham-Number is ranked lower than
99.99% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. LLY: 5.86 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LLY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.25  Med: 2.78 Max: 8.41
Current: 5.86
1.25
8.41
Earnings Yield (Greenblatt) % 3.66
LLY's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. LLY: 3.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LLY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.9  Med: 7.75 Max: 17.4
Current: 3.66
-2.9
17.4
Forward Rate of Return (Yacktman) % -5.67
LLY's Forward Rate of Return (Yacktman) % is ranked lower than
81% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. LLY: -5.67 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LLY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.2  Med: 1.15 Max: 31.3
Current: -5.67
-19.2
31.3

More Statistics

Revenue (TTM) (Mil) $23,343.00
EPS (TTM) $ 1.07
Beta0.30
Volatility12.68%
52-Week Range $73.69 - 89.97
Shares Outstanding (Mil)1,085.43

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 23,800 24,193 25,101
EBIT (Mil $) 6,067 6,631 7,327
EBITDA (Mil $) 7,309 7,890 8,790
EPS ($) 4.60 5.20 6.03
EPS without NRI ($) 4.60 5.20 6.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.79%
Dividends per Share ($) 2.36 2.46 2.48

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}